I have a novice question:
If for AML the company can use RC110 and then bridge to RC220 when it becomes available why the same approach can’t be taken for mBC? That could have us running mBC trials in the clinic now and have additional data with RC220 and show that both RC110 and RC220 have similar outcomes in terms of safety and efficacy which would chop one year off the clinical trial start and hence final transaction.
- Forums
- ASX - By Stock
- RAC
- Ann: Race Strategic Update August 2023
Ann: Race Strategic Update August 2023, page-77
-
- There are more pages in this discussion • 516 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.63 |
Change
-0.055(3.27%) |
Mkt cap ! $284.5M |
Open | High | Low | Value | Volume |
$1.67 | $1.67 | $1.61 | $152.5K | 94.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1300 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.67 | 4080 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 999 | 1.630 |
1 | 757 | 1.625 |
2 | 5717 | 1.620 |
1 | 10000 | 1.615 |
1 | 997 | 1.610 |
Price($) | Vol. | No. |
---|---|---|
1.640 | 3826 | 3 |
1.645 | 48 | 1 |
1.650 | 5 | 1 |
1.655 | 5088 | 1 |
1.670 | 4080 | 1 |
Last trade - 15.59pm 09/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |